529 / 1084
Targeted therapies?
EGFR:
The SCOPE1 trial: addition of cetuximab to standard chemoradiation for localized
esophageal cancers
Stop before phase 3 chemoradiation plus cetuximab
shorter median OS
and more grade 3 and 4 toxicities
Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. Chemoradiotherapy with or without
cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet
Oncol. 2013;14(7):627–37
HER2:
Overexpressed in gastric & GEJ tumor
Positive TOGA trial
RTOG 1010 ongoing
VEGF:
AVAGAST trial randomized inoperable locally advanced or metastatic gastric or
GEJ adenocarcinomas to bevacizumab or placebo with capecitabine and cisplatin
Survival did not reach statistical significance
Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in chinese
patients with inoperable locallyadvanced or metastatic gastric or gastroesophageal junction cancer:
Randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168–76